Cytek Biosciences (CTKB) Capital Expenditures (2020 - 2026)

Cytek Biosciences' Capital Expenditures history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Capital Expenditures rose 826.5% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 1422.44% YoY) and the FY2025 annual result came in at $129000.0, down 27.12% from the prior year.
• Capital Expenditures was $2.2 million for Q1 2026 at Cytek Biosciences, up from -$3.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $6.5 million in Q4 2022 and bottomed at -$3.1 million in Q4 2023.
• A 5-year average of $721294.1 and a median of $234000.0 in 2025 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 1199.42% — and 2025, when it slumped 3887.18%.
• Cytek Biosciences' Capital Expenditures stood at $6.5 million in 2022, then sank by 147.6% to -$3.1 million in 2023, then surged by 102.51% to $78000.0 in 2024, then slumped by 3887.18% to -$3.0 million in 2025, then surged by 173.39% to $2.2 million in 2026.
• Business Quant data shows CTKB's Capital Expenditures at $2.2 million in Q1 2026, -$3.0 million in Q4 2025, and $3.0 million in Q3 2025.